SEC Form 4 · accession 0001209191-16-098167
NEKTAR THERAPEUTICS · NKTR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Howard W Robin
Officer — President & CEO · Director
Period of report
Feb 10, 2016
Accepted (ET)
Feb 12, 2016 · 5:18 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000906709
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Feb 10, 2016 | M | 66,666 | $6.46 | A | 76,666 | D | |
| Common StockF1,F2 | Feb 10, 2016 | S | 66,666 | $11.49 | D | 10,000 | D | |
| Common Stock | holding | — | — | — | 410 | I | by spouse |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionF1 | $6.46 | Feb 10, 2016 | M | 66,666 | D | Feb 25, 2012 | Feb 24, 2016 | Common Stock | 66,666 | 0 | D |
Explanation of responses
- F1This transaction was made pursuant to a Rule 10b5-1 trading plan for stock options scheduled to expire in early 2016 as described in the Current Report on Form 8-K filed by Nektar Therapeutics on July 16, 2015.
- F2This transaction was executed in multiple trades at prices ranging from $11.16 to $11.75. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.